Stock message boards
MNV
Market News Video
MNV MNV Model Portfolios ChartZero
MNV
MNV
MNV
MNV
MNV
MNV
MNV


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
MNV Backgroundemail friendsEmail Friendsembed / linkEmbed VideorssRSS Feed standaloneLaunch Standalone Player

Pfizer Receives European Approval for Prevenar 13
Friday, December 11, 10:31 AM ET

Pfizer on Friday announced that it received European approval for its pneumoccal vaccine, Prevenar 13, for children. The bacterium can cause pneumonia, middle ear infections, meningitis, and blood infections.

The drug was actually developed by Wyeth, which was bought by Pfizer in a $68 billion deal earlier this year. The original vaccine developed by Wyeth was the company's second best selling drug, with $2.7 billion in revenue in 2008. The old version of the vaccine blocked seven versions of the bacteria, while the new one blocks thirteen.

There has been much consolidation within the pharmaceutical sector in 2009, with the $41.1 billion merger of Merck and Schering-Plough just recently completed.

For MarketNewsVideo.com, I'm Justin Shackil.

Pfizer Receives European Approval for Prevenar 13 picture